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ABSTRACT The interferon-induced, dsRNA-activated
human protein kinase (PKR) exerts antiviral and antiprolifer-
ative effects through inhibition of protein synthesis. Studies of
structur-function relationships in PKR have shown that two
dsRNA binding motifs are important for its autophosphoryla-
tion and activation by dsRNA in vitro. To correlate these
findings with the activity of PKR in vivo, we examined the
function of various PKR deletion mutants in cultured cells by
using an inducible expression system. In a reporter gene assay,
mutant forms of the kinase lacking amino acids 1-97 (A1-97)
and 104-157 (A104-157), which are required for dsRNA
binding in vitro, retained full activity in vivo. Deletion of amino
acids 233-271 (A233-271), however, abolished the transla-
tional inhibitory activity of the kinase and prevented its phos-
phorylation. Moreover, cells infected with vaccinia virus re-
combinants expressing wild-type PKR, the mutant A104-157,
or a triple deletion mutant form of PKR (A1-97, A104-157,
A186-222), developed almost complete inhibition of both viral
and cellular protein synthesis upon induction of PKR. This
inhibition of viral protein synthesis was not observed in cells
infected with a recombinant expressing A233-271 mutant
PKR. Our findins establish that the region encompassing
amino acids 233-271 of PKR is critical for kinase activity in
vivo, whereas its dsRNA binding domain is dispensable.
The interferon (IFN)-induced, dsRNA-activated human pro-
tein kinase (PKR; also termed DAI, p68 kinase, dsI, PKd,,
and P1/eIF2a protein kinase) is thought to be a key mediator
of the antiviral and antiproliferative effects of IFN (1, 2). In
the presence of dsRNA and ATP, PKR is autophosphory-
lated on several of its serine and threonine residues (3).
Autophosphorylated PKR, in turn, catalyzes the phosphor-
ylation of the a subunit of eukaryotic initiation factor 2
(eIF-2a), which leads to inhibition of protein synthesis (4).
Recent studies have demonstrated directly the antiviral func-
tion ofPKR (5, 6) and its ability to suppress growth in yeast
(7). In addition, PKR has been suggested to be a tumor
suppressor because expression of catalytically inactive mu-
tant forms of the kinase can cause malignant transformation
(8, 9). The tumor suppressor function ofPKR has also been
correlated with the induction of apoptosis (10).
The conserved kinase motifs (11) are represented in the
C-terminal half of PKR, while the N-terminal half of the
protein, which presumably plays a regulatory role, contains
three clusters of basic amino acids (aa) (12, 13). These basic
regions encompass aa 1-97, 104-157, and 233-271. Studies of
various mutants of PKR in vitro revealed the existence of a
dsRNA binding domain within the first 171 aa (7, 13-17). This
domain is composed of two divergent copies of an RNA
binding motif, each of which contains one of the basic
clusters (13). Thus, the first two basic regions, which span aa
1-97 and 104-157, are required for dsRNA binding, whereas
the third basic region, aa 233-271, is dispensable for this
function (13).
Comparable structure-function studies in vivo are ham-
pered by the toxic effects of PKR. To overcome this limita-
tion, we established an infection-transfection system in
which expression ofPKR is driven by a vaccinia virus (VV)
late promoter and regulated by Escherichia coli lacI repres-
sor/operator control elements (18). In this system, cultured
cells are infected with VV and transfected with two plasmids,
one containing the inducible PKR gene and the other carrying
a luciferase (LUC) reporter gene. Production ofPKR leads to
reduced LUC expression. We have also developed VV
recombinants in which activation of PKR leads to a severe
inhibition of both viral and cellular protein synthesis during
infection (6). These two systems provide the means to study
the structure-function relationship of PKR in vivo. In this
investigation we have analyzed the activity of deletion mu-
tants ofPKR using both the VV infection-transfection system
and the VV recombinant system. We report that the third
basic region, which spans aa 233-271, is critical for the
activation of PKR. Moreover, we show that activation of
PKR can occur in the absence of both dsRNA binding motifs
(aa 1-97 and aa 104-157). These results suggest that the
endogenous PKR may phosphorylate the transfected kinase
and that the third basic region is required for this activation.
MATERIALS AND METHODS
Construction ofW Insertional Vectors Cont Mutant
Forms of PKR. Plasmids pTL1 and pTL11 containing the
cDNAs encoding the entire human PKR gene (wild-type and
lys296--arg mutant, respectively) have been described (18).
The pTL constructs are based on a VV insertional vector,
pPR35, for inducible expression (19). It consists of the
following genetic elements: the VV late promoter p4b, two
21-bp lac operators (op), and the lac repressor gene under
control of the VV early-late promoter p7.5 (Fig. 1). The
cassette is flanked at both ends with VV thymidine kinase
sequences to provide sites of insertion into the VV genome.
A schematic representation ofwild-type and deletion mutants
ofPKR is shown in Fig. 1. Plasmid pTL1 was digested with
BamHI and Nco I, the ends were filled with Klenow frag-
ment, and the vector was self-ligated to generate pTL12,
containing a deletion of aa 1-97 (A1-97), equivalent to Al
(13). Plasmids A2 and A3 (13) harboring deletions of aa
104-157 and 233-271, respectively, were treated with Sty I to
excise the fragments that contain the deletions, and the
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virus; p.i., postinfection; pfu, plaque-forming units; dsRNA, double-
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FIG. 1. Schematic representation of inducible insertional VV vector pPR35 (19) and different deletion mutants ofPKR. TKL, VV thymidine
kinase gene, left end; TKR, VV thymidine kinase gene, right end; p4b, VV late promoter; op, lac operator; p7.5, VV early-late promoter; Lac
I, lac repressor. Arrows indicate the direction ofgene expression. Hatched boxes I, II, and III indicate three regions that are rich in basic amino
acids within the N terminus ofPKR. The numbers above the hatched boxes denote the amino acid residues. The catalytic domain is comprised
of 270 aa of the C terminus ofPKR and is shown in the dotted box. K296R indicates a single point mutation, which converts the lysine residue
at aa 296 to arginine. WT, wild-type PKR.
resultant fragments were inserted between equivalent sites in
pTL1 to generate pTL7 and pTL8, respectively. Plasmid
pTL1 was digested with BsaAI and Pme I and self-ligated to
yield pTL19 containing a deletion of aa 186-222. The cloning
strategy used for pTL12 was used to generate the double
deletions pTL20 (A1-97, A186-222) and pTL21 (A1-97,
A104-157) from pTL19 and pTL7, respectively. The strategy
used for pTL19 was applied to pTL7 to yield pTL22 (A104-
157, A186-222). Plasmid pTL22 was further treated in the
same manner as used to generate pTL12 to yield pTL23
containing deletions from aa 1-97, 104-157, and 186-222. All
constructs were confirmed by DNA restriction analysis.
Growth of Cells and Viruses. Monolayer cultures ofAfrican
green monkey kidney BSC-40 cells were grown in Dulbecco's
modified Eagle's medium (DMEM) containing 10% newborn
calfserum (GIBCO/BRL). The Western Reserve (WR) strain
of VV and VV recombinants were grown and prepared as
described (20).
Generation ofW Recombinants Expressing Mutant Forms
of PKR. Recombinant VVs expressing the wild-type or
lys296-+arg PKR have been described (6). Viruses express-
ing the deletion mutants A104-157 (WR68KA2), A233-271
(WR68KA3), and A1-97, A104-157, A186-222 (WR68KATri)
were generated using the pTL7, pTL8, and pTL23 plasmids,
respectively, according to the procedure described previ-
ously (21). Recombinant viruses were selected with 5'-
bromodeoxyuridine, and two rounds of plaque purification
yielded homogeneous virus stocks. The PKR insertion site in
the VV genome was confirmed by Southern blot analysis
using total DNA from infected cells.
Infection-Transfection Analysis. BSC-40 cells were infected
for 1 hr withW at 2 plaque-forming units (pfu) per cell. After
removing the inoculum, the cells were transfected (Lipofect-
ACE; BRL) with plasmids expressing PKR for 3 hr and then
incubated with fresh DMEM containing 2% newborn calf
serum either with or without 1.5 mM isopropyl P-D-
thiogalactoside (IPTG) for 18 hr.
Immunoprecipitation Analysis. BSC-40 cells grown in
60-mm plates were infected at 2 pfu per cell with VV and
transfected with 10 pg of indicated plasmids in the absence or
in the presence of 1.5 mM IPTG. At 20 hr postinfection (p.i.)
cells were metabolically labeled for 3 hr with 50 tCi of
[32P]orthophosphate per ml (1 Ci = 37 GBq) in phosphate-free
medium. Cell extracts were prepared and immunoprecipi-
tated as described (6), using rabbit polyclonal antibody
specific for human PKR (13) [1:50 dilution in phosphate-
buffered saline (PBS) with 5% Blotto (nonfat dry milk)].
Immunoprecipitates were analyzed by 8% SDS/PAGE and
autoradiography.
Measurement of LUC Activity. BSC-40 cells grown in
12-well Limbro plates were infected at 2 pfu per cell with VV
and cotransfected with 1 pg ofPKR plasmid together with 1
pg of pPR15 (19), with or without 1.5 mM IPTG. Plasmid
pPR15 contains the LUC reporter gene under control of the
VV p4b late promoter, the same promoter that drives the
expression of the PKR constructs but without the lac repres-
sor/operator element. LUC activity in cell extracts was
measured at 24 hr p.i. (22, 23).
Immunoblot Analysis. For transient infection-transfection
expression of PKR, BSC-40 cells grown in 12-well Limbro
plates were infected at 2 pfu per cell with VV and transfected
with 2 pg ofPKR plasmid, with or without 1.5 mM IPIG. At
24 hr p.i., cells were washed twice with PBS and extracts
were collected in lx SDS-reducing sample buffer (31 mM
Tris-HCl, pH 6.8/2% SDS/5% 2-mercaptoethanol/5% glyc-
erol/0.01% bromophenol blue). Proteins were separated by
8% SDS/PAGE, transferred to nitrocellulose membrane, and
allowed to react with mouse polyclonal antibodies against
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PKR (18) (1:250 dilution in PBS with 5% Blotto) followed by
immunoperoxidase staining. For recombinant virus studies,
BSC-40 cells grown in 12-well plates were mock-infected or
infected at 5 pfu per cell with recombinant VV in the absence
or presence of 1.5 mM ITG. Cell extracts were collected at
24 hr p.i. and analysis ofPKR was done as described above.
To detect VV proteins, identical samples were separated by
10% SDS/PAGE, transferred, and allowed to react with
rabbit polyclonal antibodies against VV (1:1000 dilution in
PBS with 5% Blotto).
RESULTS
Expression and Phosphorylation of Mutant PKR in Trans-
fected Cells. The protein kinase PKR is activated by dsRNA
in a reaction that is accompanied by autophosphorylation.
We demonstrated previously that induction ofwild-type PKR
in transfected cells leads to inhibition of cotransfected re-
porter gene expression (18). This inhibition requires enzy-
matically active PKR and thus provides a convenient system
in which to study the structure-tunction relationship ofPKR
in vivo. To this end, we generated a panel of plasmids
expressing various deletion mutants of PKR under the con-
trol of an inducible promoter (Fig. 1). The mutants contained
single, double, or triple deletions within the N-terminal half
of the kinase, spanning its dsRNA binding domain as well as
other regions, but sparing the conserved kinase domain. To
examine the expression and autophosphorylation of PKR,
BSC-40 cells were infected with VV and transfected with
plasmids containing different deletion mutants of the protein
kinase.
After induction of the kinase with IPTG and metabolic
labeling with [32P]orthophosphate, cell extracts were immu-
noprecipitated with rabbit polyclonal antibodies against hu-
man PKR (13). SDS/PAGE analysis of the immunoprecipi-
tates revealed different sizes of activated human PKRs as
well as background phosphorylation of the endogenous mon-
key kinase, p69 (Fig. 2A). As previously described (18), we
detected an increased phosphorylation of wild-type PKR
with the addition ofIPTG. Deletion of either the second basic
region (aa 104-157) or the region between the second and
third basic regions (aa 186-222) had no effect on PKR
phosphorylation (lanes 7 and 8 and lanes 11 and 12). Sur-
prisingly, however, autophosphorylation of the deletion mu-
tant lacking the third basic region (aa 233-271) was greatly
reduced (lanes 9 and 10). The catalytically inactive
lys296--arg mutant was also poorly phosphorylated (lanes 5
and 6), as reported previously (6). A phosphoprotein ofabout
43 kDa was coimmunoprecipitated; it probably represents a
protein related to PKR such as its breakdown product (24).
Furthermore, double deletion (A104-157, A186-222) and
triple deletion (A1-97, A104-157, A186-222) mutants ofPKR,
which lack either one or both of the dsRNA binding motifs
but retain residues 233-271, were still phosphorylated (lanes
13-16), suggesting that the third basic region (aa 233-271) is
critical for autophosphorylation of PKR. As shown by West-
ern blot analysis (Fig. 2B), the lack of phosphorylation of
A233-271 or lys296->arg PKR mutants cannot be attributed
to instability of these kinases. In addition, the degree of
induction of PKR proteins seems to be inversely related to
their activity, presumably because PKR down-regulates its
own synthesis (6, 25).
Inhibition of Translation by Mutant Forms of PKR. To
assess the ability of the deletion mutants to inhibit protein
synthesis, we cotransfected the kinase vectors with a plasmid
carrying the reporter gene, LUC. Inhibition ofLUC activity
is a reflection of inhibition of protein synthesis and not of
transcriptional regulation (18). As shown in Fig. 3, upon
induction with IPTG most of the deletion mutants inhibited
LUC activity to a similar extent as the wild-type PKR
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FIG. 2. Expression and autophosphorylation of deletion mutants
of PKR in vivo. (A) Immunoprecipitation analysis. BSC-40 cells
grown in 60-mm plates were infected with 2 pfu per cell of wild-type
VV and independently transfected with 10 jg of mutant PKR
plasmids specified. At 20 hr p.i., cells were metabolically labeled
with [32P]orthophosphate for 3 hr. Cell extracts were immunopre-
cipitated with rabbit polyclonal antibody against PKR (13) and
analyzed by 8% SDS/PAGE followed by autoradiography. Arrow-
heads denote transfected mutants or wild-type PKR. Molecular mass
markers in kDa are shown to the left. (B) Western blot analysis.
BSC-40 cells, after infection-transfection, were lysed at 24 hr p.i. and
extracts were analyzed by 8% SDS/PAGE followed by immunoblot-
ting with mouse polyclonal antibodies specific for PKR (18). Lanes
1 and 2, W-infected cells that were not transfected with any plasmid.
(80-85%). The mutant that lacks the second basic region
(A104-157) was less active, but the triple mutant, which lacks
almost all of the N-terminal half of the protein except for the
third basic region, was essentially as active as wild-type
PKR. The only deletion mutant that was inactive in terms of
inhibiting the levels of LUC was the deletion mutant that
lacked the third basic region, 4233-271. The catalytically
inactive mutant, lys296--arg, also did not inhibit LUC ac-
tivity as expected (18). These results show that the third basic
region, aa 233-271, is important for the activation ofPKR and
that activation ofPKR can occur in the absence ofboth ofthe
dsRNA binding motifs, aa 1-97 and 104-157.
Expesion of A233-271 Mutant PKR Fails To Inhibit Viral
Protein Synthesis. The observation that a mutant PKR that
lacks both of its dsRNA motifs can still be active was very
surprising; therefore, we needed to confirm the ability of
deletion mutants to inhibit virus protein synthesis in vivo. For
this purpose, we generated thrte VV recombinants express-
ing mutant PKR lacking the second basic region (A104-157),
the third basic region (A233-271), or the entire N-terminal
half of the kinase except the third basic region (A1-97,
A104-157, A186-222). Immunoblot analysis oflysates of cells
infected with these VV recombinants demonstrated that the
addition of IPTG induced expression of PKR and that the
deletion mutants ofPKR are as stable as the full-length PKR.
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FIG. 3. Deletion in the third basic region (A233-271) of PKR
results in an inactive kinase. BSC-40 cells grown in 12-well plates
were infected (2 pfu per cell) withW and independently transfected
with 1 jg ofLUC plasmid pPR15 together with 1 ;&g of the plasmids
shown. At 24 hr p.i., cells were collected and LUC production was
measured. Average LUC activity measured in a single experiment,
each performed in duplicate, is shown. In all assays, LUC activity
obtained in the absence of IPTG was normalized to 100%, and the
values refer to the percentage ofLUC activity found in induced cells
relative to uninduced cells. These experiments were carried out at
least three times with <10% variation seen between samples. WT,
wild-type PKR.
In fact, the deletion mutant proteins accumulated to levels
higher than wild-type PKR (Fig. 4A). Induction of the A104-
157 mutant or of the A1-97, A104-157, A186-222 triple
deletion mutant resulted in a severe inhibition of viral protein
synthesis in cultured cells, to a similar extent as the wild-type
PKR (Fig. 4B, lanes 11-14). In cells infected with a VV
recombinant expressing A233-271 mutant PKR (Fig. 4B,
lanes 9 and 10), however, the level of viral protein synthesis
was the same as that in cells infected with wild-type virus
lacking the PKR gene (Fig. 4B, lanes 3 and 4) or with the
recombinant virus carrying the gene for the catalytically
inactive lys296--*arg mutant (Fig. 4B, lanes 7 and 8). These
results are in accordance with the LUC data (Fig. 3) and
reinforce the validity of the transient infection-transfection
assay in assessing the activity ofPKR. Virus yields were also
not affected in cells infected with VV recombinant,
WR68KA3, while VV production was severely reduced in
cells infected with VV recombinants, WR68KA2 and
WR68KATri (data not shown). Thus, the third basic region,
but not the first or second, is required for inhibition of viral
protein synthesis.
DISCUSSION
In this report we have used two systems to conduct a
structure-function analysis of the human PKR, one based on
transient infection-transfection and the other based on VV
recombinants.- In both systems, expression of various dele-
tion mutants of PKR can be induced with IPTG in cultured
cells. The major advantage of the transient infection-
transfection system is that, by using a reporter gene, it allows
us to conveniently measure the activity of the transfected
PKR gene, while with VV recombinants we measure directly
inhibition ofvirus protein synthesis during infection. Because
of the toxicity of PKR, in vivo structure-function studies of
the kinase have been limited to date. In one of these studies,
Feng et al. (17) used a yeast cell growth inhibition assay to
show that PKR deletions between aa 39 and 50 and aa 58 and
69 eliminated the slow-growth phenotype caused by expres-
sion of wild-type PKR. Other studies examined the ability of
PKR to inhibit its own synthesis in transfected COS cells
(25-27). Thomis and Samuel (25) showed that the catalyti-
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FIG. 4. Effects of PKR mutants on viral protein synthesis.
BSC-40 cells were mock-infected or infected at 5 pfu per cell with
different recombinant VVs, and cell extracts were collected at 24 hr
p.i. (A) Proteins were resolved by 8% SDS/PAGE, transferred to
nitrocellulose membrane, and allowed to react with mouse polyclo-
nal antibodies specific for PKR (18). (B) Proteins were resolved by
1o0 SDS/PAGE, transferred, and allowed to react with rabbit
polyclonal antibodies against VV.
cally inactive lys296-+arg mutant kinase was expressed at
about 30-fold higher levels than wild-type PKR, and similar
observations were presented by Barber et al. (26) and con-
firmed here (Figs. 2B and 4A). Deletion of aa 156-243 had
little effect on the kinase, but removal of aa 91-243 led to a
20- to 25-fold reduction of kinase activity and a 70-fold
increase in its expression (26). Interestingly, a point mutation
that converted lysine-64 to glutamic acid abolished the RNA
binding activity and resulted in a 15-fold increase in its
expression (27). Based on these and other in vitro studies (7,
13-17), one would expect that deletions of either the first (aa
1-97) or the second (aa 104-157) dsRNA binding motifs
would be deleterious to kinase activity in tissue culture cells.
Surprisingly, however, we found that deletions in both
dsRNA binding motifs (aa 1-97 and aa 104-157), either
separately or in combination, were permitted without affect-
ing the ability ofPKR to inhibit expression of a reporter gene
or virus genes in our system. In fact, the only requirement for
the activation ofPKR in our system was the presence of the
third basic region (aa 233-271), which lies outside the RNA
binding domain.
Why is the third basic region important for PKR function?
The sequence of this region does not offer any obvious clues,
and it is possible that it serves some structural role in
maintaining enzyme conformation that will become evident
10554 Biochemistry: Lee et al.
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only when the enzyme's three-dimensional structure is
known. Based on secondary structure predictions, this region
may adopt a helical form, raising the possibility that it is
equivalent to the A helix, which is contiguous to the catalytic
core of several protein kinases (28). However, we do not
think this is very likely for two reasons. (i) The A helix is
important for stability but not for function (28), whereas the
third basic region of PKR is important for function but
probably not for stability. (ii) It lacks the diagnostic tryp-
tophan that seems to play an important part in A helix
interactions with the kinase core (28). An alternative hypoth-
esis is suggested by the observation that its removal greatly
reduces phosphorylation, indicating that the region contains
sequences important for this activity, or the phosphorylation
sites themselves. The finding of several phosphorylation sites
in this region supports the latter possibility, but major sites
are also present elsewhere in the protein (D. Taylor and
M.B.M., unpublished observations).
How can the enzyme become active in the absence of its
RNA binding domain? One possibility is that deletions in
either or both dsRNA binding motifs (aa 1-97 and aa 104-157)
render the kinase constitutively active. We demonstrated
previously that in cells infected with a recombinant virus
expressing wild-type PKR, inhibition of protein synthesis
does not occur before 6 hr p.i.; furthermore, the kinase is not
Phosphorylated between 2 and 5 hr p.i. despite the fact that
the maximal synthesis ofPKR was occurring at 5 hr p.i. (6).
This suggests that wild-type PKR is not constitutively active
in our system, requiring accumulation of an activator. When
cells were infected with a virus expressing the deletion
mutant PKR, which lacks both of its dsRNA binding motifs
(WR68KATri), inhibition of protein synthesis also did not
occur before 6 hr p.i. and the mutant PKR was not phos-
phorylated before 5 hr p.i. (data not shown). These obser-
vations argue against the idea that deletions of both dsRNA
binding motifs result in constitutively active kinase. More-
over, the isolated kinase domain of PKR does not autophos-
phorylate or phosphorylate eIF-2a in vitro (S.R.G. and
M.B.M., unpublished observations). A second possibility is
that the endogenous monkey cell PKR phosphorylates and
activates the mutant kinases, provided they are not enzy-
matically crippled. On this basis, mutants in the RNA binding
domain could be activated, whereas the lys296--arg and
A233-271 mutants would be refractory. Although this would
seem to pose a problem in regulating the enzyme by gener-
ating all-or-none activation, the trans-phosphorylation of
inactive PKR variants by the active enzyme has recently
been obtained (ref. 29; C. Schmedt, S.R.G., D. Taylor, and
M.B.M., unpublished observations). Finally, there may be
endogenous activators other than dsRNA that function in
vivo. It has been assumed that dsRNA is the physiological
activator of PKR, but direct proof is scarce and heparin and
other molecules with polyanionic structure have been shown
to activate PKR in vitro (30). Our study indicates that
activator(s) other than dsRNA should be considered. Iden-
tifying the nature of these activators should shed some light
on the physiological functions of PKR.
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